Skip to main content
    R

    ResMed Inc (RMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $238.23
    -1.30 (-0.54%)

    Market Cap: $33.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ResMed Inc (RMD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect ResMed (RMD) to earn $12.14 per share in the fiscal year ending Jun 30, 2027, on revenue of $5.83B. Of 20 analysts, 9 rate the stock Buy or Strong Buy, 10 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Jun 30, 2028, the EPS consensus is $13.23.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 45% of the ratings.

    RatingAnalystsShare
    Strong Buy210.0%
    Buy735.0%
    Hold1050.0%
    Sell15.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 9.0% and revenue estimates rise 6.5%.

    Fiscal year ending Jun 30, 2027
    $12.14
    EPS consensus, revenue $5.83B
    Fiscal year ending Jun 30, 2028
    $13.23
    EPS consensus, revenue $6.21B
    Next report
    Jan 27, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Jun 30, 2027$12.14$12.02 to $12.2321$5.83B$5.78B to $5.96B29
    Jun 30, 2028$13.23$12.71 to $13.7321$6.21B$5.93B to $6.48B29

    Quarterly Estimates

    Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Dec 31, 2026, at $2.99, and highest for the quarter ending Jun 30, 2027, at $3.22.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.99$2.93 to $3.1313$1.46B$1.45B to $1.48B15
    Mar 31, 2027$3.06$3.02 to $3.1013$1.46B$1.44B to $1.48B15
    Jun 30, 2027$3.22$3.02 to $3.4217$1.51B$1.44B to $1.58B18

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 9 upward and 28 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Jun 30, 202889
    Quarter ending Dec 31, 202616
    Quarter ending Mar 31, 2027013

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has risen 1.6% from $11.95.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Jun 30, 2027$12.14$12.09$12.09$12.08$11.95+1.6%
    Fiscal year ending Jun 30, 2028$13.23$13.26$13.23$13.21$13.01+1.6%
    Quarter ending Dec 31, 2026$2.99$3.02$3.03$3.04$3.01-0.8%
    Quarter ending Mar 31, 2027$3.06$3.14$3.15$3.14$3.04+0.4%

    Frequently Asked Questions About RMD

    What is the RMD stock forecast?

    Consensus analyst estimates put ResMed's EPS at $12.14 for the fiscal year ending Jun 30, 2027, on revenue of $5.83B. The consensus rating from 20 analysts is Hold.

    How do analysts rate RMD stock?

    Of 20 analysts covering ResMed, 2 rate it Strong Buy, 7 Buy, 10 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from RMD next year?

    For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is $12.14, with estimates from $12.02 to $12.23 from 21 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is $13.23, with estimates from $12.71 to $13.73 from 21 analysts.

    What revenue do analysts expect from ResMed next year?

    For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $5.83B, with estimates from $5.78B to $5.96B. For the fiscal year ending Jun 30, 2028, the consensus revenue estimate is $6.21B, with estimates from $5.93B to $6.48B.

    How many analysts cover RMD?

    20 analysts rate ResMed stock, and 21 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.